An antibody treatment for the rare autoimmune disorder, neuromyelitis optica spectrum disorder, has received a positive opinion from the European Medicines Agency following two studies showing that the therapy reduced the chance of disease relapse. The treatment, Enspryng (satralizumab), was developed by the Roche Group. It targets the interleukin-6 receptor which is believed to play a role in the inflammation associated with the disease.
Enspryng was reviewed for adults and adolescents who are positive for the pathogenic antibodies, AQP4, an indicator of the disease.